MarisaHaydeeMiceliMD

Infectious Disease • Ann Arbor, MI

Physician

Join to view full profile

Dr. Miceli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Miceli's full profile

Already have an account?

Office
1500 East Medical Center Dr
3rd Floor Taubman Center Recp D
Ann Arbor, MI 48109
Phone+1 734-936-5899

Fax+1 734-615-2156

Education & Training

Corewell Health East Beaumont (Dearborn)Residency, Internal Medicine, 2009 - 2012
University of New Mexico School of MedicineFellowship, Infectious Disease, 2007 - 2009
University of Buenos AiresClass of 1992

Certifications & Licensure

MI State Medical License 2009 - 2025
NM State Medical License 2007 - 2009
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Publications & Presentations

PubMed

Evaluation of Turnaround Times for Antigen Testing in Hospitalized Patients With Histoplasmosis and Blastomycosis.
Liam M Dalton, Carol A Kauffman, Blair Richards, Marisa H Miceli
Open Forum Infectious Diseases. 2024-09-01
Oral Lipid Nanocrystal Amphotericin B (MAT2203) for the Treatment of Invasive Fungal Infections.
Liam M Dalton, Carol A Kauffman, Marisa H Miceli
Open Forum Infectious Diseases. 2024-07-01
1 citations
Reply to Williams et al.
M Hong Nguyen, Luis Ostrosky-Zeichner, Peter G Pappas, Thomas J Walsh, Joseph Bubalo
Open Forum Infectious Diseases. 2024-03-01

Press Mentions

Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. Mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMIDApril 18th, 2023
Patient with Candida Krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical ResolutionOctober 12th, 2023
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 23rd, 2024